Hoth Therapeutics filed two provisional patent applications with the U.S. Patent and Trademark Office, expanding the ...

FDA approval of Vanda’s Nereus marks a rare and meaningful regulatory milestone, introducing the first new pharmacologic ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...

Sanofi is positioning its late-stage pipeline and R&D discipline as the long-term growth bridge beyond Dupixent, against a backdrop of solid financial performance and mixed investor optimism. In today ...

In 2024, AbbVie’s presentation at the conference focused on its recent acquisitions of ImmunoGen and Cerevel. AbbVie paid ...

By the beginning of 2025, it was clear the GLP-1 drugs were going to remain a major part of the industry. Pfizer used its presentation at the 43 rd JP Morgan Healthcre Conference to detail plans to ...

ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and licensed to Sanofi. The ADEL-Sanofi agreement is valued at over $1.04 billion ...

Lilly’s return to the JP Morgan Healthcare Conference comes as the company seeks to shift the narrative from last year’s ...

Johnson & Johnson announced that management will hold a fireside chat at 11:15 am, Est, on Monday, January 12, 2026. It will also be presented as a live audio webcast on J&J’s investor relations site.

AI’s true promise is turning clinical development from a bottleneck into a throughput engine for human health. Drug discovery ...

The FDA has approved Novo Nordisk’s Wegovy pill to reduce excess body weight, support weight management, and maintain weight ...

Roche’s executives at JP Morgan 2025 spoke candidly about the company’s need to be more deliberate in its approach on how ...